Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.64
-0.0300-1.80%
Post-market: 1.60-0.0400-2.44%18:56 EDT
Volume:214.78K
Turnover:349.72K
Market Cap:25.94M
PE:-2.27
High:1.70
Open:1.66
Low:1.56
Close:1.67
52wk High:2.35
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:0.55
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7218
EPS(LYR):-15.6529
ROE:-87.92%
ROA:-23.70%
PB:3.75
PE(LYR):-0.10

Loading ...

Company Profile

Company Name:
Allarity Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
8
Office Location:
123 E. Tarpon Ave.,Tarpon Springs,Florida,United States
Zip Code:
34689
Fax:
- -
Introduction:
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Gerald W. McLaughlin
Chairman of Board and Director
Thomas H. Jensen
Chief Executive Officer and Director
Jesper Hoiland
Director
Laura E. Benjamin
Director

Shareholders

Name
Position
Thomas H. Jensen
Chief Executive Officer and Director
Jeffrey S. Ervin
Chief Financial Officer
Jeremy R. Graff
Chief Development Officer and President
Steen Knudsen
Chief Scientific Officer